Rafael Holdings Announces Exciting Rights Offering
Rafael Holdings, Inc. is stepping up its game with a new rights offering aimed at raising $25 million to bolster its commitment to groundbreaking pharmaceutical developments. This initiative is particularly focused on advancing Trappsol® Cyclo™, a promising treatment under investigation for Niemann-Pick Disease Type C1 (NPC1). This funding is crucial as it supports the potential launch of this innovative therapy following positive interim results from the upcoming clinical trial.
Details of the Rights Offering
The rights offering is designed for existing stockholders and holders of the company’s public warrants, creating an opportunity for them to acquire additional shares of Rafael Holdings’ Class B common stock. As of the Record Date, which is set for a future day, holders can secure subscription rights to purchase shares at an attractive price of $1.28 each. Each subscription right, distributed on a non-transferable basis, will allow holders to acquire a fraction of a share, rounding down to the nearest whole share. This arrangement is structured to encourage participation while ensuring equitable access for shareholders.
Ownership and Subscription Timeline
The timeline for this rights offering includes an Ownership Day where shareholders must acquire shares to participate. Following this date, the subscription period will open, allowing holders to exercise their rights for a limited time. This includes a straightforward approach where fractional shares are not issued, ensuring clarity and simplicity in the purchasing process.
Key Pointers for Participants
Participants interested in the rights offering should note that the subscription rights can only be exercised during the specified period, providing a clear window for action. Potential investors are encouraged to engage with the subscription materials and consult their financial advisors to make informed decisions.
Standby Purchase Agreement
To further solidify the offering, Howard Jonas, the Executive Chairman of Rafael Holdings, has agreed to enter into a Standby Purchase Agreement. This agreement ensures that any shares not subscribed for will be purchased by Jonas at the set subscription price, demonstrating strong confidence in the company’s future and its offerings.
Background Information on Rafael Holdings
Rafael Holdings is committed to innovation within the pharmaceutical industry. Alongside its involvement in the development of Trappsol® Cyclo™, the company has stakes in several other biotechnology ventures. These include partnerships with organizations focused on various therapeutic areas, showcasing Rafael’s broad interest in advancing healthcare technologies. As the company navigates these exciting prospects, the focus on NPC1 highlights its dedication to addressing significant medical needs.
Frequently Asked Questions
What is the purpose of the rights offering?
The rights offering aims to raise $25 million to support the development and potential launch of Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C1.
How can existing shareholders participate in the rights offering?
Shareholders must be recorded by the designated date to receive subscription rights, allowing them to purchase shares at a subscription price of $1.28 each during the offering period.
Who is responsible for overseeing the rights offering?
D.F. King & Co., Inc. has been appointed as the Information Agent for the rights offering, assisting with inquiries and providing necessary materials to shareholders.
Are the subscription rights transferable?
No, the subscription rights are non-transferable and must be exercised within the specific subscription period.
What should holders consider before participating?
Holders are encouraged to carefully review the subscription materials and consult with financial advisors before making a decision on whether to exercise their subscription rights.
